Treatment of Overactive Bladder With Anticholinergic Agents

Active, not recruiting

• Conditions: Overactive Bladder

• Registration Number: NCT07046156
• Lead Sponsor: Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital

Brief Summary

This study aims to evaluate the efficacy and adverse effect incidence of three different anticholinergics (oxybutinin, propiverine, and tolterodine) that are used in children with overactive bladder.

Detailed Description

A total of approximately 150 patients with overactive bladder will be evaluated retrospectively. Clinical and demographic data and voiding diaries of these patients will be evaluated. For this purpose, patients will be divided into mainly three groups according to the anticholinergic agent used.

Study Timeline

• Study Start: 2022-09-01
• Status Verified: 2025-06
• Study First Submitted: 2025-06-23
• Study First Submitted QC: 2025-06-23
• Last Update Submitted: 2025-06-23
• Primary Completion: 2025-06-30
• Study First Posted: 2025-07-01
• Last Update Posted: 2025-07-01
• Study Completion: 2026-06-01

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

• Patients diagnosed with overactive bladder
• Patients treated with an anticholinergic

Exclusion Criteria

• Presence of anatomical or neurological problems
• Patients with missing data

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Number of patients treated with anticholinergic	6 months
Number of patients with drug related adverse effects	1 month

Trial Locations

Locations (1)

Sancaktepe Sehit Prof dr Ilhan Varank Training and Research Hospital; 🇹🇷 Istanbul, Turkey